MNOV - メディシノバ (MediciNova Inc.) メディシノバ

 MNOVのチャート


 MNOVの企業情報

symbol MNOV
会社名 Medicinova Inc (メディシノバ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 メディシノバ(MediciNova Inc.)は主に米国市場を中心とした疾患の治療のための小分子治療薬を取得・開発するバイオ製薬企業である。同社の主要製品はMN-166(ibudilast)、MN-001(tipelukast)、MN-221(bedoradrine)、MN-029(denibulin)等がある。MN-166は経口で、抗炎症薬および神経保護剤であり、進行性多発性硬化症、筋萎縮性側索硬化症、物質依存および中毒などの神経的疾患の治療薬を開発する。MN-001(tipelukast)は非アルコール性脂肪性肝炎と特発性肺線維症などの線維性疾患を治療する経口の低分子化合物である。MN-221は静脈内注入で喘息の急性増悪を治療する。MN-029固形腫瘍癌を治療する。   メディシノバは、米国のバイオ医薬品企業。多発性硬化症、薬物依存、非アルコ―ル性脂肪性肝炎(NASH)、肺線維症、神経因性疼痛薬、慢性閉塞性肺疾患(COPD)、筋萎縮性側索硬化症(ASL)、気管支喘息急性発作などに対する治療薬の開発、商業化に従事。本社はカリフォルニア州。   MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of serious diseases for the treatment of diseases with unmet medical need. Its development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.
本社所在地 4275 Executive Square Suite 300 La Jolla CA 92037 USA
代表者氏名 Jeffrey Himawan ジェフリー・ヒマワン
代表者役職名 Independent Chairman of the Board
電話番号 +1 858-373-1500
設立年月日 36770
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 9人
url www.medicinova.com
nasdaq_url https://www.nasdaq.com/symbol/mnov
adr_tso
EBITDA EBITDA(百万ドル) -15.23832
終値(lastsale) 11.66
時価総額(marketcap) 488309991.18
時価総額 時価総額(百万ドル) 431.77330
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 367.61052
当期純利益 当期純利益(百万ドル) -13.74516
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 MediciNova Inc. revenues was not reported. Net loss increased 32% to $7.7M. Higher net loss reflects Research and development and patents increase of 69% to $3M (expense) General and administrative increase of 25% to $5M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.17 to -$0.19.

 MNOVのテクニカル分析


 MNOVのニュース

   Opioid Use Disorder Market Trends Estimates High Demand By 2027 - Indivior, Alkermes, MediciNova, Orexo, Camurus and Omeros  2020/11/03 08:10:51 OpenPR
Opioid Use Disorder (OUD) is a type of chronic disorder that is associated with repeated self-administration of opioids, prolonged self-administration of opioid drugs and compulsive use of opioid drugs. Patients addicted to medical opioids, and the patients addicted to non-medical
   MediciNova Stock Spikes on Coronavirus-Vaccine Progress  2020/09/23 14:37:28 The Street
MediciNova's shares jumped after the drugmaker reported that its coronavirus-vaccine prototype showed antibody production in mice.
   The Daily Biotech Pulse: Coronavirus Vaccine Updates From J&J & MediciNova, Australian Regulatory Nod For GW Pharma  2020/09/23 08:05:00 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) …
   Mid-Afternoon Market Update: Nasdaq Surges 140 Points; MediciNova Shares Spike Higher  2020/07/27 14:50:00 Benzinga
Toward the end of trading Monday, the Dow traded up 0.19% to 26520.77 while the NASDAQ rose 1.35% to 10,503.25. The S&P also rose, gaining 0.56% to …
   MediciNova to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit  2020/07/20 10:30:00 GlobeNewswire
LA JOLLA, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and…
   Opioid Use Disorder Market Trends Estimates High Demand By 2027 - Indivior, Alkermes, MediciNova, Orexo, Camurus and Omeros  2020/11/03 08:10:51 OpenPR
Opioid Use Disorder (OUD) is a type of chronic disorder that is associated with repeated self-administration of opioids, prolonged self-administration of opioid drugs and compulsive use of opioid drugs. Patients addicted to medical opioids, and the patients addicted to non-medical
   MediciNova Stock Spikes on Coronavirus-Vaccine Progress  2020/09/23 14:37:28 The Street
MediciNova's shares jumped after the drugmaker reported that its coronavirus-vaccine prototype showed antibody production in mice.
   The Daily Biotech Pulse: Coronavirus Vaccine Updates From J&J & MediciNova, Australian Regulatory Nod For GW Pharma  2020/09/23 08:05:00 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) …
   Mid-Afternoon Market Update: Nasdaq Surges 140 Points; MediciNova Shares Spike Higher  2020/07/27 14:50:00 Benzinga
Toward the end of trading Monday, the Dow traded up 0.19% to 26520.77 while the NASDAQ rose 1.35% to 10,503.25. The S&P also rose, gaining 0.56% to …
   MediciNova to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit  2020/07/20 10:30:00 GlobeNewswire
LA JOLLA, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and…
   MediciNova Stock Spikes on Coronavirus-Vaccine Progress  2020/09/23 14:37:28 The Street
MediciNova's shares jumped after the drugmaker reported that its coronavirus-vaccine prototype showed antibody production in mice.
   The Daily Biotech Pulse: Coronavirus Vaccine Updates From J&J & MediciNova, Australian Regulatory Nod For GW Pharma  2020/09/23 08:05:00 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) …
   Mid-Afternoon Market Update: Nasdaq Surges 140 Points; MediciNova Shares Spike Higher  2020/07/27 14:50:00 Benzinga
Toward the end of trading Monday, the Dow traded up 0.19% to 26520.77 while the NASDAQ rose 1.35% to 10,503.25. The S&P also rose, gaining 0.56% to …
   MediciNova to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit  2020/07/20 10:30:00 GlobeNewswire
LA JOLLA, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and…
   The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact  2020/06/24 12:07:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Acceleron Pharma Inc (NASDAQ: XLRN ) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) Avidity Biosciences Inc (NASDAQ: RNA ) (went public June 12) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (went public June 12) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Crispr Therapeutics AG (NASDAQ: CRSP ) (moved on analyst action) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Dyadic International, Inc. (NASDAQ: DYAI ) Editas Medicine Inc (NASDAQ: EDIT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 メディシノバ MNOV MediciNova Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)